🍪 CompoundTalk uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsPublic SquareRetatrutide anticipation thread — what are your questions for Phase 3? Page 5

Retatrutide anticipation thread — what are your questions for Phase 3?

rick_sfbay Mon, Mar 23, 2026 at 11:14 PM 32 replies 903 viewsPage 5 of 7
Dr.RenalNash
VIP Member
1,234
7,890
Mar 2024
Nashville, TN
Apr 3, 2026 at 11:31 PM#21
pam_columbus said:
That is right, and it stops being right at the edges.

Same pattern here, and in the same order. I had assumed I was the exception until I read this.

Last edited: Apr 4, 2026 at 4:31 AM
1 24wei_SG
Reply Quote Save Share Report
kate.chem
VIP Member
3,890
17,654
Dec 2023
California
Apr 8, 2026 at 6:42 AM#22
pam_columbus said:
That is right, and it stops being right at the edges.

There is a second half to this that has not been said yet. The gap between trial results and real-world results is consistent and it is not fraud. Trial participants get titration by protocol, scheduled contact, free drug and dietetic support; removing that infrastructure costs a few percentage points every time it has been measured. When your own curve sits below the published mean, that is the likeliest explanation before anything about you or your material.

2 0VanRx_Mike, steve_okc
Reply Quote Save Share Report
bri_stats
Member
789
3,456
May 2024
Seattle, WA
Apr 12, 2026 at 1:51 PM#23

The figures, for anyone assembling their own picture. Keep the original post as written when you update it, and add the correction underneath. An edited-away mistake is invisible to the next person who makes it.

3 1TomFromTexas, mike.trainer_LA, sarah_nash92
Reply Quote Save Share Report

PeptideMeter — Independent Peptide Analytics

Community-driven peptide testing and vendor rating platform. Transparent results. Unbiased analysis. Trusted by thousands.

View Results
MikeNYC_runner
Member
378
1,678
Jul 2024
New York, NY
Apr 16, 2026 at 8:58 PM#24

A narrower follow-up, since the general answer is now clear:

How to read a result like this without either dismissing it or over-reading it, since the summaries all read like press releases?

4 2GenomicsKate, Dr.ObesityMed, HealthEcon_DC and 1 other
Reply Quote Save Share Report
gary_naperville
Member
245
1,123
Oct 2024
Naperville, IL
Apr 21, 2026 at 4:02 AM#25
bri_stats said:
Keep the original post as written when you update it, and add the correction underneath.

This is where I part company with the consensus forming above. The counter-case has not been addressed. Somebody upthread described the situation that does not fit, and the thread moved on rather than engaging with it, which is the failure mode this board is supposed to avoid.

5 3RickReta_CO, PharmHunterJen, TomTeleRx and 2 others
Reply Quote Save Share Report

Similar Threads

SELECT trial 4-year follow-up data released — sustained MACE reduction16 replies
GLP-1 receptor agonists and thyroid C-cell concerns — evidence review19 replies
Is there a ceiling effect for GLP-1-mediated weight loss?20 replies
Comparative pharmacokinetics: semaglutide vs tirzepatide vs retatrutide6 replies
My 18-month semaglutide journey — comprehensive data log20 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register